Artificial Intelligence Prognostic Model for Sepsis Based on Time Series Analysis

December 6, 2024 updated by: Chi Zhang, West China Hospital

Construction of an Artificial Intelligence Prognostic Prediction Model for Sepsis Based on Time Series Analysis

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. It is one of the leading causes of death and disability worldwide, with an inpatient mortality rate of 10-20%. Sepsis is a severe complication in critically ill patients and can lead to septic shock and multiple organ dysfunction syndrome (MODS), usually triggered by severe trauma, surgery, and infections. Despite the availability of advanced diagnostic, therapeutic, and monitoring technologies, the incidence and mortality of sepsis remain high, posing a significant global challenge to the medical community. Over 49 million people worldwide develop sepsis annually, with approximately 11 million deaths, resulting in a mortality rate of about 15%-25%.

This study aims to develop a prognosis prediction model for sepsis patients using a neural network architecture (Transformer algorithm), based on time-series data. The primary outcome observed is the mortality outcome of sepsis patients. The goal of the research is to enhance the early identification of high-risk sepsis patients, thereby optimizing the timing of sepsis treatment and intervention and improving the accuracy of prognosis prediction for sepsis patients.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

1. Research Background Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. It is one of the leading causes of death and disability worldwide, with an inpatient mortality rate of 10-20%. Sepsis is a severe complication in critically ill patients and can lead to septic shock and multiple organ dysfunction syndrome (MODS), usually triggered by severe trauma, surgery, and infections. Despite the availability of advanced diagnostic, therapeutic, and monitoring technologies, the incidence and mortality of sepsis remain high, posing a significant global challenge to the medical community. Over 49 million people worldwide develop sepsis annually, with approximately 11 million deaths, resulting in a mortality rate of about 15%-25%.

2. Research Objectives and Content

  1. Research Objective This study aims to develop a prognosis prediction model for sepsis patients using a neural network architecture (Transformer algorithm), based on time-series data. The primary outcome observed is the mortality outcome of sepsis patients. The goal of the research is to enhance the early identification of high-risk sepsis patients, thereby optimizing the timing of sepsis treatment and intervention and improving the accuracy of prognosis prediction for sepsis patients.
  2. Research Content 2.1 Inclusion Criteria Patients diagnosed with sepsis at West China Hospital of Sichuan University from January 2020 to December 2023.

    2.2 Exclusion Criteria 1) Age under 18 years; 2) Gender unknown; 3) Incorrect or invalid discharge diagnosis; 4) Hospitalization period less than 24 hours; 5) Missing data exceeds 30%. 2.3 Sample Size 3,000 cases. 2.4 Data to be Collected A retrospective analysis of the clinical data of patients diagnosed with sepsis at West China Hospital of Sichuan University from January 2020 to December 2023 will be conducted. The baseline data of patients (including age, gender, comorbidities, history of malignant tumors, lesion sites, pathological types, etc.), occurrence of severe complications, total hospital stay, survival time, and other relevant information will be summarized to build a time-series-based prognosis prediction model for sepsis mortality risk.

  3. Clinical Research Ethical Principles and Requirements This clinical research will comply with the Declaration of Helsinki issued by the World Medical Association and the relevant regulations set forth by the National Health and Family Planning Commission of the People's Republic of China concerning the Ethical Review of Biomedical Research Involving Human Subjects. The research will only utilize retrospective medical records and/or specimens, with all personal identifiers removed. There will be no risk to the subjects, nor will it negatively impact their rights or health. Therefore, informed consent is waived. The research data will be stored at West China Hospital of Sichuan University, accessible to the researchers, supervising departments, and the ethics review committee. Any public reports related to the research findings will not disclose the personal identity of the subjects. We will make every effort within the legal framework to protect the privacy and personal medical information of the subjects.

Study Type

Observational

Enrollment (Actual)

3641

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Chi Zhang

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Retrospective analysis of clinical data of patients diagnosed with sepsis at West China Hospital of Sichuan University from January 2020 to December 2023. Review and summarize the baseline data of patients (including age, gender, comorbidities, history of malignant tumors, lesion location, pathological type, etc.), occurrence of serious complications, total length of hospital stay, survival time, and construct a time-series based mortality risk prognosis prediction model for sepsis patients.

Description

Inclusion Criteria:

  • Patients clinically diagnosed with sepsis at West China Hospital of Sichuan University from January 2020 to December 2023

Exclusion Criteria:

  • Under the age of 18;
  • Gender unknown;
  • Incorrect or invalid discharge diagnosis;
  • The hospitalization time is less than 24 hours;
  • Data information is missing by more than 30%.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Survival Group
No interventions
Non-survival Group
No interventions

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Biomarker level
Time Frame: 5 Years
Including inflammatory markers (such as C-reactive protein (CRP), interleukins (IL-6, IL-10), and procalcitonin (PCT)) and metabolic markers (such as lactate levels and arterial blood gas pH values) for sepsis prognostic analysis.
5 Years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SOFA score
Time Frame: 5 Years
Standard measure of organ function for sepsis.
5 Years
Length of ICU stay
Time Frame: 5 Years
Reflects the severity of illness and critical care needs.
5 Years
APACHE II score
Time Frame: 5 Years
Standard measure of severity for sepsis.
5 Years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2020

Primary Completion (Actual)

December 31, 2023

Study Completion (Actual)

December 31, 2023

Study Registration Dates

First Submitted

November 30, 2024

First Submitted That Met QC Criteria

December 6, 2024

First Posted (Estimated)

December 9, 2024

Study Record Updates

Last Update Posted (Estimated)

December 9, 2024

Last Update Submitted That Met QC Criteria

December 6, 2024

Last Verified

December 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • No.126 in 2024

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe